Elevated levels of solTNFR2 are observed in a variety of human pathophysiological conditions but regulation of TNFR2 levels during disease is not well understood. We found that solTNFR2 levels were increased following influenza infection or live-attenuated influenza virus challenge in mice and humans, respectively. As influenza-specific CD8 + T cells up-regulated expression of TNFR2 after infection in mice, we hypothesized that CD8 + T cells contributed, in part, to solTNFR2 production after influenza infection and were interested in the mechanisms by which CD8 + T cells regulate TNFR2
Introduction
TNFR2 is a member of the TNFR superfamily, a family of proteins that functions to regulate T cell activation, proliferation, and survival [1] . TNFR2 mediates these effects by binding to mem-or solTNF-a [2] [3] [4] . TNFR2 is expressed on the surface following activation of naive CD8 + T cells, where it can function as a costimulatory molecule, lowering the threshold for activation and enhancing proliferation [5] [6] [7] [8] [9] . TNFR2 2/2 initially impairs T cell proliferation and survival, a result of, in part, reduced expression of IL-2 [9, 10] . This early defect in survival can be overcome with the addition of exogenous IL-2, and after becoming effector cells, TNFR2 2/2 CD8 + T cells are highly resistant to activation-induced cell death [7, 11] . These studies suggest that TNFR2 expression has an important role in CD8 + T cell activation and turnover. One mechanism by which CD8 + T cells can regulate the effects of TNFR2 signaling is to decrease surface expression of TNFR2 in a process known as ectodomain shedding [12] . Activation of CD8 + T cells by TCR stimulation results in the production of solTNFR2 with a concomitant decrease in memTNFR2 expression [5, 6, 12] . The release of TNFR2 from the cell surface may reduce the sensitivity of the activated CD8 + T cell to the effects of TNF-a. Additionally, the released solTNFR2 is bioactive and can bind solTNF-a to regulate TNF-a signaling [13] [14] [15] . Regulation of solTNF-a is critically important in health and disease, as solTNF-a levels often determine the extent of injury during pathophysiological processes [16, 17] . Interestingly, increased levels of solTNFR2 have been observed in a variety of pathophysiological processes, including systemic lupus erythematosus, rheumatoid arthritis, and chronic viral hepatitis, suggesting that solTNFR2 regulation of solTNF-a bioavailability may impact disease progression and that the levels of solTNFR2 may reflect the extent of immune responses [18] [19] [20] .
ADAM17 has been implicated in the shedding of TNFR2 from neutrophils, macrophages, and other cell types [21, 22] . Whereas it has been reported that CD8 + T cells express ADAM17 [23, 24] , its role in shedding TNFR2 from activated CD8 + T cells has not been investigated. The regulation of ADAM17-mediated processing is complex and requires coordinated temporal and spatial signaling for shedding of TNFR2 to occur. These signals include phosphorylation of ADAM17, localization of ADAM17 and its substrates to lipid rafts, and dissociation from its endogenous inhibitor [25] [26] [27] [28] [29] . ADAM17 has been shown to mediate a constitutive level of shedding of its ligands, but different stimuli can up-regulate activity of ADAM17 and increase ligand shedding [30] . Notably, distinct stimuli elicit disparate signaling pathways that are responsible for the activation-dependent increase in ADAM17 activity [26, 31, 32] . A previous study investigating shedding of TNFR2 by human CD8 + T cells used the nonphysiologic stimulus PMA in combination with anti-CD3 to stimulate the cells [12] . In light of these interesting findings, an important objective of our study was to investigate how physiologic stimuli regulate shedding of TNFR2 by CD8 + T cells.
Our interest in understanding the regulation of ADAM17 and mechanisms of TNFR2 shedding by CD8 + T cells originates from our studies investigating the shedding of TNF-a by CD8 + T cells during influenza infection [16] . Herein, we report that ADAM17 is the principal protease required for TNFR2 shedding induced by physiologic TCR signaling in influenza-specific, effector CD8 + T cells. We also elucidate key signaling intermediates between TCR agonism and ADAM17-mediated TNFR2 shedding and discuss the importance of TNFR2 shedding in regulating the availability of solTNF-a during influenza infection.
MATERIALS AND METHODS

Reagents
TAPI was purchased from Peptides International (Louisville, KY, USA). Brefeldin A was purchased from LC Laboratories (Woburn, MA, USA). ERK1/2 selective inhibitor U0126 and antibodies for phospho-p44/p42 MAPK ERK1/2 (4370) and p44/p42 MAPK ERK 1/2 (9102) were from Cell Signaling Technologies (Danvers, MA, USA). Actin polymerization inhibitors latrunculin A and cytochalasin D were purchased from Enzo Life Sciences (Farmingdale, NY, USA). Lipid raft disrupters, methylb-cyclodextrin and filipin III, PMA, and FITC-conjugated CtxB subunit were purchased from Sigma-Aldrich (St. Louis, MO, USA). The following antibodies were from BioLegend (San Diego, CA, USA) as unconjugated or conjugated to FITC, PE, PerCP/Cy5.5, PE-Cy7, APC, APC-Cy7, or Pacific Blue: CD3 (17A2), CD8 (5.3-6.7), CD44 (IM7), CD62L (MEL-14), CD69 (H1.2F3), TNF-a (MP6-XT22), IFN-g (XMG1.2), TNFR2 (TR75-89), donkey anti-rabbit (Poly4064), goat anti-Armenian hamster IgG (Poly4055), and b-actin (Poly6221). Goat anti-Armenian hamster IgG was from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Anti-mouse CD16/32 was from DartLab (Lebanon, NH, USA). APC-conjugated tetramer specific for the immunodominant, H-2D 
CD8 + T cell culture
NP 366-374 -specific CD8 + T cells were generated as described previously [17] . 
Flow cytometry
Cells were first blocked with anti-mouse CD16/32 and then stained with specific antibodies or isotype controls, as described previously [16] . For intracellular cytokine staining, cells were maintained in brefeldin A until fixation and then permeabilized and stained with anti-TNF-a and anti-IFN-g. 
Human LAIV challenge
Nasal-swab specimens were obtained before immunization and on days 2, 4, and 7 after an initial dose of LAIV, as described previously [33] , and assessed for solTNFR2 by ELISA (R&D Systems 
Statistical analyses
Statistical analyses were performed with GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Two-tailed, unpaired t-test with 95% confidence interval or Wilcoxon signed rank test with 95% confidence interval was used to analyze differences between groups, whereas 1-or 2-way ANOVA with 95% confidence interval was used to analyze differences among 3 or more groups or among groups over time, respectively. Data are presented as the mean 6 SD.
RESULTS
solTNFR2 production is increased in humans after LAIV challenge
Expression of solTNFR2 is increased in a variety of inflammatory conditions in humans [18] [19] [20] ; however, it was unknown whether influenza virus infection increased solTNFR2 levels. To test whether influenza virus increased solTNFR2 levels, we examined solTNFR2 levels from nasalswab samples recovered from humans before and after challenge with LAIV. Before challenge, there were detectable levels of solTNFR2 in nasal-swab specimens ( Fig. 1A and B) .
Following primary LAIV challenge, we observed an increase in solTNFR2 levels in the nasal-swab specimens recovered from a number of the patients (Fig. 1A) , and when we examined the peak solTNFR2 levels that occurred after LAIV challenge, we found that there was a significant increase in solTNFR2 levels compared with preimmunization levels (Fig. 1B) . Thus, similar to other inflammatory diseases and as proof of translational significance, solTNFR2 levels are increased after LAIV challenge in humans.
solTNFR2 production is increased after influenza infection in mice
To investigate further the significance of increased solTNFR2 levels after influenza virus challenge, we used a murine model of experimental influenza infection, in which mice were inoculated with virus intranasally. Similar to humans, solTNFR2 was detectable in samples recovered from the airways and sera of mice before infection ( Fig. 2 A and B) . Following intranasal infection with influenza infection, we observed significant increases in airway and serum solTNFR2 levels ( Fig. 2A and B) . The peak levels of solTNFR2 occurred between days 7 and 10 postinfection, which also corresponded to a time at which we observed the peak airway levels of other proinflammatory cytokines, such as solTNFa ( Fig. 2C ) and IFN-g (Fig. 2D) . Interestingly, there were significant, positive correlations between airway levels of solTNFR2 and weight-loss morbidity ( Fig. 2E ), airway albumin levels ( Fig. 2F ), a surrogate for vascular leakage, or total cells in the airway (Fig. 2G) , suggesting that TNFR2 levels may be indicative of the extent of immune responses and severity of disease during influenza infection. To test the latter, we challenged mice with different doses of virus and found that increasing the initial dose of viral challenge raised airway levels of solTNFR2 (Fig. 2H) . Thus, influenza infection in mice increases TNFR2 is expressed on and shed by influenza-specific effector CD8 + T cells
As it has been reported that memTNFR2 is expressed on influenza-specific CD8 + T cells in the lungs of infected mice [4, 34] , we examined whether CD8 + T cells contributed to the increase in solTNFR2 levels following influenza infection in mice. CD8 + T cells were detectable in the airways as early as day 5 postinfection and peaked in absolute numbers between days 7 and 10 ( Fig. 3A) , which corresponded to the peak in airway and serum solTNFR2 levels ( Fig. 2A and B) . memTNFR2 was detectable on CD8 + T cells in the airways and lung-draining MLN, the site of CD8 + T cell priming, on day 7 postinfection (Fig. 3B) . We found that the vast majority of CD8 + T cells expressing memTNFR2 in the MLN was NP 366-374 specific, indicating that influenza-specific CD8 + T cells expressed memTNFR2 upon activation in the MLN before trafficking to the lung (Fig. 3B) . As shedding of TNFR2 by human CD8 + T cells has been shown to be sensitive to metalloproteinase inhibition [12] , we tested whether CD8 + T cells contributed to solTNFR2 expression in the influenza-infected lung by intratracheally administering a broadspectrum metalloproteinase inhibitor, TAPI, on day 10 postinfection. TAPI treatment significantly reduced solTNFR2 levels in the airways (Fig. 3C) , with a concomitant increase in surface expression of memTNFR2 on CD8 + T cells recovered from the airways (Fig. 3D) , indicating that CD8 + T cells contributed to the increased levels of solTNFR2 after influenza infection. Consistent with previous reports [21, 22] , Figure 2 . solTNFR2 levels are increased after influenza infection in mice. WT mice were infected with A/PR/8/34 influenza virus, and solTNFR2 levels in the (A) airway and (B) serum were assessed by ELISA on the days indicated. Airway levels of (C) solTNF-a and (D) IFN-g were analyzed by ELISA on the days indicated. The levels in influenza-infected mice were compared with baseline values from naive mice for statistical analysis (*P , 0.05; **P , 0.01; ***P , 0.005). N.D., not detected. The correlations of (E) percent baseline weight change, (F) airway albumin levels, or (G) total cells recovered from the airway with airway solTNFR2 levels throughout the course of infection were determined by linear regression analysis. The slope of each linear regression was found to be significantly nonzero (,0.0001), as calculated from an F test. (H) WT mice were infected with 10, 1, or 0.1 times the median lethal dose of A/PR/8/34 influenza virus, and on day 7 postinfection, solTNFR2 levels in the airway were assessed by ELISA. Data represent means 6 SD. Data are representative of 2 independent experiments with 3-5 mice/group. *P , 0.05; ***P , 0.005.
TAPI treatment also increased surface expression of memTNFR2 on other immune cells (Supplemental Fig. 1 ), indicating that CD8 + T cells contributed, in part, to the increase in solTNFR2 levels in the influenza-infected lung.
ADAM17 is required for shedding of TNFR2 by effector CD8 + T cells
To examine further the regulation of TNFR2 shedding by influenza-specific CD8 + T cells, we generated bulk cultures of NP 366-374 -specific CD8 + T cells and examined their capacity to shed TNFR2 in vitro. TCR stimulation reduced memTNFR2 expression, which was blocked by TAPI treatment (Fig. 4A and B) . Interestingly, TAPI treatment of unstimulated CD8 + T cells increased memTNFR2 expression (Fig. 4C) , and treatment of CD8 + T cells with brefeldin A, which blocks protein trafficking, reduced memTNFR2 levels (Supplemental Fig. 2 ), indicating that TNFR2 was constitutively recruited to the surface and shed from effector CD8 + T cells. Furthermore, TAPI treatment inhibited constitutive and TCR-stimulated production of solTNFR2 (Fig. 4D) . Whereas ADAM17 has been identified as a protease responsible for shedding TNFR2 on many cell types [21, 22] , it was unknown whether it was responsible for shedding TNFR2 by CD8 + T cells. To test whether ADAM17
was required for TNFR2 shedding, we generated ADAM17
NP 366-374 -specific CD8 + T cells that expressed a deletion in the zinc catalytic domain of ADAM17, resulting in functional inactivation of ADAM17. Following TCR stimulation of ADAM17 2/2 CD8 + T cells, there was no decrease in memTNFR2 levels, in contrast to the decreased memTNFR2 levels observed on activated WT CD8 + T cells ( Fig. 4A and B) . Furthermore, constitutive and activation-induced solTNFR2 production was inhibited in ADAM17 2/2 CD8 + T cells compared with WT CD8 + T cells (Fig. 4E) . Taken together, these data identify ADAM17 as the protease required for TNFR2 shedding by effector CD8 + T cells.
ADAM17 is required in cis for shedding of TNFR2 by CD8 + T cells
We next examined whether ADAM17 could shed TNFR2 in "trans" or "cis" in vitro by coculturing ADAM17 2/2 CD8 + T cells, which lack the functional enzyme but express the substrate on the surface with TNFR2 2/2 CD8 + T cells, which possess the functional enzyme but lack the substrate. We did not observe any decreases in memTNFR2 expression after TCR stimulation on ADAM17 2/2 CD8 + T cells alone or cocultured with TNFR2
2/2 CD8 + T cells (Fig. 5A) . Coculture of ADAM17 2/2 CD8 + T cells with TNFR2
2/2 CD8 + T cells also resulted in no detectable production of solTNFR2 (Fig. 5B) . Importantly, we observed solTNF-a production following TCR stimulation by TNFR2 2/2
CD8
+ T cells alone and in the coculture conditions, indicating that ADAM17 was functional (Fig. 5C ). Furthermore, IFN-g production was not impaired in any of the conditions, suggesting that all of the CD8 + T cells were functionally active under these conditions (Fig. 5D ). To test this in vivo, we adoptively transferred WT or ADAM17 2/2 NP 366-374 -specific CD8 + T cells into influenza-infected TNFR2 2/2 mice and examined solTNFR2 levels. We recovered a similar frequency and total number of transferred cells from the airways (Fig. 5E ), indicating that WT and ADAM17 2/2 CD8 + T cells were capable of trafficking to the infected lung to recognize antigen. solTNFR2 was detectable in the airways and serum of TNFR2 2/2 recipients of WT CD8 + T cells (Fig. 5F ). In contrast, TNFR2 2/2 recipients of ADAM17 2/2 CD8 + T cells had no detectable solTNFR2 levels ( Fig. 5F ), indicating that host ADAM17 was unable to cleave TNFR2 in trans on ADAM17 2/2 CD8 + T cells. Airway levels of solTNF-a were also markedly reduced in TNFR2 2/2 recipients of ADAM17 2/2 CD8 + T cells compared with WT CD8 + T cells (Fig.  5G) . Importantly, no differences in the airway levels of IFN-g were observed (Fig. 5H) , suggesting that WT and ADAM17
2/2
CD8
+ T cells were capable of being activated to mediate effector functions. Taken together, these observations reveal that 
Shedding of TNFR2 is dependent on strength of TCR signaling and MAPK ERK1/2 activation
As ADAM17 is required for TNFR2 and TNF-a shedding by CD8 + T cells and the strength of TCR signaling can regulate the induction of different CD8 + T cell effector functions [35] , we next examined the key signaling intermediates for TNFR2 shedding and cytokine production. With the use of increasing concentrations of NP 366-374 peptide as a surrogate for increasing TCR signaling strength, we found that the activation threshold for TNFR2 shedding by NP 366-374 -specific CD8 + T cells occurred near a concentration of 10 212 M NP 366-374 peptide (Fig. 6A) . We observed a similar activation threshold for IFN-g and TNF-a expression (Fig. 6B) . As ADAM17-mediated processing of CD62L by CD8 + T cells was shown to be dependent on TCR signal transduction through the MAPK ERK1/2 pathway [32] , and ERK1/2 signaling has also been shown to be important for trafficking, maturation, and activation of ADAM17 [25, 26] , we next examined whether ERK1/2 signaling was important for TNFR2 shedding by effector CD8 + T cells. First, we examined the activation threshold for activation of ERK1/2 signaling and found that the threshold for ERK1/2 phosphorylation was similar to the activation threshold for TNFR2 shedding (Fig. 6C) , indicating that ERK1/2 signaling and TNFR2 shedding were tightly regulated by TCR signaling. Next, we blocked TCR-stimulated ERK1/2 signaling with U0126, a highly selective inhibitor of ERK1/2, and found that U0126 treatment blocked the TCRstimulated decrease in memTNFR2 levels (Fig. 6D) and TCRstimulated solTNFR2 production (Fig. 6E) . Treatment of cells with actin-remodeling inhibitors or cholesterol-depleting or -inhibitory agents, the latter that block lipid raft formation, also impaired ERK1/2 signaling and TNFR2 shedding (Fig. 6F) , indicating that MAPK ERK1/2 signaling was critical for activation-induced TNFR2 shedding.
TNFR2 shedding by activated CD8 + T cells contributes to the regulation of solTNF-a availability
As we observed similar activation thresholds for TNF-a expression and TNFR2 shedding, we assessed the possibility that the increased solTNFR2 levels functioned, in part, to limit the availability of solTNF-a by use of antibody blockade of TNFR2 or mice lacking TNFR2. Antibody blockade or genetic TNFR2 2/2 resulted in increased levels of solTNF-a after influenza infection ( Fig. 7A and B) , suggesting that TNFR2 functioned, in part, to regulate solTNF-a levels. TNFR2 2/2 had no impact on the ability of mice to control or clear virus, indicating that the increased solTNF-a levels were not a result of increased viral titers (Fig.  7C) . Next, we investigated whether TNFR2 shedding by activated CD8 + T cells could modulate the levels of CD8 + T cell-produced solTNF-a. TNFR2 and TNF-a were recruited to the immunologic synapse of activated CD8 + T cells (Fig. 8A) , indicating that solTNFR2 would be spatially available to regulate solTNF-a levels. Moreover, TNFR2 shedding preceded TNF-a expression and release by activated CD8 + T cells (Supplemental Fig. 3A) , consistent with previous reports [12] . Interestingly, memTNFR2 levels decreased over time, even in the presence of TAPI, and this may have been a result of, in part, an autocrine interaction between memTNFR2 and memTNF-a, as antibody blockade of 2/2 CD8 + T cells was determined by flow cytometry. ELISA was used to measure (F) serum and airway levels of solTNFR2 and airway levels of (G) solTNF-a and (H) IFN-g. Data represent means 6 SD. Data are representative of 2 independent experiments with each condition conducted in triplicate or each group containing 3-4 mice. *P , 0.05; ***P , 0.005. Fig. 3B ) or genetic deletion of TNF-a (Supplemental Fig. 3C ) restored memTNFR2 levels in the presence of TAPI. These data demonstrate that TNFR2 shedding and TNF-a expression are tightly linked and suggest that loss of memTNFR2 from the activated CD8 + T cell may desensitize the cell to the effects of TNF-a, and the solTNFR2 that is released may affect the availability CD8 + T cell-produced TNF-a. To test the latter possibility, we treated activated WT CD8 + T cells with blocking antibody for TNFR2 and found that this enhanced the total levels of solTNF-a recovered in the supernatant (Fig. 8B) . Next, we examined solTNF-a production in the complete absence of TNFR2. Whereas TNFR2 2/2 and WT CD8 + T cells produced similar total levels of intracellular TNF-a (Fig. 8C) , we detected increased levels of solTNF-a in the supernatant of activated TNFR2
TNFR2 (Supplemental
2/2 CD8 + T cells compared with WT CD8 + T cells (Fig. 8D) . Addition of recombinant solTNFR2 to activated TNFR2 2/2 CD8 + T cells significantly reduced the level of solTNFa detected in a dose-dependent manner, and this effect was abrogated with the addition of blocking antibody for TNFR2 (Fig.  8E) . Taken together, these data suggest that shed TNFR2 from activated CD8 + T cells functions, in part, to regulate the availability of solTNF-a released from these activated cells.
DISCUSSION
In this study, we demonstrated that effector CD8 + T cells constitutively express and shed TNFR2, and we identified ADAM17 as the protease responsible for shedding of TNFR2. Moreover, ADAM17 and TNFR2 were required in cis for shedding to occur. TCR-stimulated shedding required actin remodeling and lipid raft formation and was dependent on the strength of TCR signaling and the MAPK/ERK pathway. TNFR2 shedding was increased after influenza infection in mice, where it had a role in regulating the availability of solTNF-a. Additionally, we observed an increase in solTNFR2 levels after LAIV challenge in humans, suggesting that the shed receptor may have a role in regulating solTNF-a levels during influenza infection in humans.
TNFR2 expression was inducible and observed on recently activated influenza-specific CD8 + T cells in the lung-draining lymph node during influenza infection. TCR stimulation of these cells resulted in shedding of TNFR2 from the cell surface and increased levels of solTNFR2, consistent with previous studies that used human T cells [5, 6, 12] . TNFR2 was constitutively recruited to the surface of effector CD8 + T cells as inhibition of protein trafficking by brefeldin A reduced memTNFR2 levels and subsequently reduced activation-induced solTNFR2 production. This is similar to the reduced memTNFR1 and activation-induced solTNFR1 production observed in human endothelial cells treated with brefeldin A [36] . This demonstrates that effector CD8 + T cells actively maintain TNFR2 on the cell surface and may sensitize the cell to the effects of TNF-a. Thus, it has been hypothesized that TNFR2 shedding functions, in part, to desensitize an activated cell from TNFR2-dependent TNF-a signaling effects [37] . Several of our observations support this hypothesis. First, following activation, CD8 + T cells continuously shed TNFR2 and maintained low expression of the receptor on the cell surface, despite continuous trafficking of TNFR2 from intracellular stores to the cell membrane. Moreover, TNFR2 shedding preceded TNF-a expression and release. Second, contrary to a prior report that suggested myeloid-derived suppressor cell-expressed ADAM17 operated in trans to cleave CD62L on T cells [24] , we found that ADAM17 functioned in cis to shed TNFR2, which would allow for stricter control of ligand and receptor shedding on the activated CD8 + T cell. In this prior report, the ability of ADAM17 to function in trans was not tested directly but assumed by differences in ADAM17 expression on myeloid-derived suppressor cells and T cells [24] . Third, the activation threshold of TNFR2 shedding was similar to that of TNF-a expression, indicating that the CD8 + T cell would completely shed memTNFR2 when TCR signaling was strong enough to induce TNF-a production by that cell. Finally, inhibition of ADAM17-mediated shedding appeared to result in an autocrine interaction of memTNF-a with memTNFR2. Therefore, an important question that remains to be investigated is how expression and shedding of TNFR2 impact CD8 + T cell effector function. However, we were unable to address this in the current study by use of ADAM17 2/2 CD8 + T cells or broadspectrum protease inhibitors, as both also inhibit TNF-a shedding. The ideal reagent to test these hypotheses would be a mouse that exclusively expresses noncleavable memTNFR2, which would allow one to dissect the impact of TNFR2 shedding from TNF-a shedding. We also found that TNFR2 had an important role in regulating the availability of solTNF-a during influenza infection, as solTNFR2 levels were increased in the airways and serum after influenza infection in mice and TNFR2 2/2 or antibody blockade of TNFR2 enhanced solTNF-a levels in the airways. solTNFR2 production by activated influenza-specific CD8 + T cells was also capable of reducing the availability of solTNF-a produced by these cells in vitro. Moreover, solTNFR2 and solTNF-a were recruited to the immunologic synapse of activated CD8 + T cells, raising the possibility that solTNFR2 was shed concurrently with solTNF-a to limit TNF-a signaling in the target cell or leakage of solTNF-a from this junction. The regulation of solTNF-a levels during influenza infection is of critical importance, as we have demonstrated previously that ADAM17-mediated processing of TNF-a by influenza-specific CD8 + T cells was required for the development of severe and lethal lung injury in mice [16] . In humans, solTNF-a levels in nasal lavage samples have been shown to correlate with the onset and severity of disease symptoms in experimental [38, 39] and community-acquired [40, 41] influenza infection. As we observed elevated levels of solTNFR2 in humans after LAIV challenge, the extent by which solTNFR2 limits the availability of solTNF-a may have important implications for disease progression. Thus, future studies are required to understand the full consequence of TNFR2 expression and shedding in regulating solTNF-a levels during influenza infection and the impact this has on pulmonary pathology.
It is important to note that other than impacting our ability to detect solTNF-a levels (which we infer as reduced bioavailability), our study does not elucidate whether solTNFR2 is acting as an agonist or antagonist for solTNF-a signaling. Previous reports have demonstrated that solTNFR2 can reduce solTNF-a-mediated cytotoxicity in vitro, supporting an antagonistic role for solTNFR2 [13] [14] [15] . It has also been reported that solTNFR2 can function as an agonist, enhancing solTNF-a-mediated cell growth in vitro [15] . These studies often used supraphysiologic levels of solTNFR2 or recombinant TNFR2 to achieve these effects, and even though we observed increased solTNF-a levels following TNFR2 blockade in vitro and in vivo, likewise, high levels of recombinant TNFR2 were needed in our studies to reduce solTNF-a levels in vitro. Therefore, whether solTNFR2 acts as an agonist or antagonist in vivo remains unclear and may depend, in part, on the form of solTNFR2. Whereas dimeric solTNFR2 molecules have been shown to reduce serum solTNF-a levels following injection of LPS in mice, monomeric solTNFR2 molecules actually enhanced serum solTNF-a levels, indicating that the oligomeric status of the receptor may dictate its biologic function [42] . This may have important implications, as we show here that solTNFR2 levels are increased after LAIV challenge in humans, and increased levels of solTNFR2 have been shown to correlate with the severity of a number of diseases [18] [19] [20] , including the extent of morbidity and pulmonary pathology during influenza infection in mice, as demonstrated here. Given the success of anti-TNF-a therapies in a variety of diseases, despite the presence of elevated levels of solTNFR2 during these diseases, it is tempting to speculate that solTNFR2 may function as a carrier of solTNF-a, prolonging TNF-a bioactivity, and thus, solTNFR2 may also represent an attractive therapeutic target. Alternatively, the majority of solTNFR2 may be functionally inactive or impaired and serve only as a surrogate for the extent of immune responses or severity of disease. However, expression of disease-relevant levels of human TNFR2 in mice results in multiorgan inflammation, independent of TNF-a [43] , providing further support that specific antagonism of TNFR2 may be beneficial in limiting influenza immunopathology.
In conclusion, we have shown that TCR signaling in effector CD8 + T cells activates the MAPK/ERK pathway and induces TNFR2 shedding by ADAM17. With similar activation thresholds for TNF-a production and TNFR2 shedding, it seems likely that processing of TNFR2 by activated CD8 + T cells functions to modify the sensitivity of the activated cell to TNF-a. Meanwhile, the shed receptor may function to regulate the bioavailability of solTNF-a. Future studies of TNFR2 shedding by CD8 + T cells will be aimed at understanding its role in T cell homeostasis and its impact on TNF-a-mediated pathology. AUTHORSHIP M.P.D. participated in the experimental design, performed the experiments, interpreted the data, and wrote the manuscript. K.H.E., P.F.W., and E.B.T. participated in experimental design, data interpretation, and manuscript revision. R.I.E. participated in experimental design, data interpretation, and writing of the manuscript. 
